Connecticut 2018 Regular Session

Connecticut Senate Bill SB00379

Introduced
3/1/18  
Refer
3/1/18  
Refer
3/1/18  
Report Pass
4/5/18  
Refer
4/12/18  
Refer
4/12/18  

Caption

An Act Limiting Changes To Health Insurers' Prescription Drug Formularies.

Impact

The implications of SB 379 on state law are significant, primarily reinforcing the rights of patients regarding their prescribed medications. By ensuring patients have the right to maintain access to necessary drugs throughout the coverage period, the law aims to protect individuals with chronic conditions who might rely on specific prescriptions. This reform comes amid a broader effort to make healthcare more equitable, suggesting that the bill is a proactive measure to limit abrupt alterations in medication availability that can impact patient health outcomes.

Summary

Substitute Bill No. 379 aims to place limitations on how health insurers can alter their lists of covered prescription drugs. Specifically, the bill prohibits health insurance policies from removing or reclassifying covered prescription drugs in a way that increases costs for patients, except under certain circumstances. These circumstances include instances where the drug is not deemed medically necessary, or if it is determined to be unsafe or ineffective by relevant medical authorities. The required notice before any such changes must be communicated to policyholders at least sixty days in advance, thereby providing them and their healthcare providers with time to adjust treatment plans if necessary.

Sentiment

General sentiment around the bill appears largely supportive, particularly among patient advocacy groups and healthcare providers, who see it as a critical step toward patient protection and stability. However, there are concerns from some insurance industry representatives regarding potential increases in costs or reduced flexibility in managing formularies. The discussions indicate a clear divide between those prioritizing consumer rights and those focusing on the operational aspects of healthcare costs and insurance providers' financial sustainability.

Contention

Notably, points of contention include the balance between patient rights and the flexibility of insurers to manage costs effectively. Proponents argue that the bill is necessary to prevent insurers from arbitrarily removing essential medications, which could lead to detrimental health consequences for patients. Critics, however, caution that overly stringent regulations might limit insurers' ability to adapt to new medical information or market conditions, potentially leading to financial repercussions that could impact premium rates and insurance affordability.

Companion Bills

No companion bills found.

Similar Bills

CA AB2789

Health care practitioners: prescriptions: electronic data transmission.

CA AB852

Health care practitioners: electronic prescriptions.

CA AB149

Controlled substances: prescriptions.

TX SB594

Relating to the regulation of prescriptions for controlled substances, including certain procedures applicable to electronic prescriptions for Schedule II controlled substances.

TX HB2246

Relating to certain procedures applicable to electronic prescriptions for Schedule II controlled substances.

TX HB2766

Relating to electronic and other controlled substance prescriptions under the Texas Controlled Substances Act; authorizing a fee.